Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Warfarin therapy: evolving strategies in anticoagulation.

J D Horton1, B M Bushwick

  • 1Department of Pharmacy, York Hospital, PA 17405, USA.

American Family Physician
|February 25, 1999
PubMed
Summary

Warfarin is a commonly prescribed oral anticoagulant for preventing blood clots. Safe and effective use requires understanding its complex dosing, potential drug interactions, and careful management, especially in elderly patients, to avoid bleeding risks.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bochdalek hernia in the adult: demographics, presentation, and surgical management.

Hernia : the journal of hernias and abdominal wall surgery·2010
Same author

SREBPs: transcriptional mediators of lipid homeostasis.

Cold Spring Harbor symposia on quantitative biology·2003
Same author

Sterol regulatory element-binding proteins: transcriptional activators of lipid synthesis.

Biochemical Society transactions·2002
Same author

Decreased lipid synthesis in livers of mice with disrupted Site-1 protease gene.

Proceedings of the National Academy of Sciences of the United States of America·2001
Same author

Identification of a mammalian long chain fatty acyl elongase regulated by sterol regulatory element-binding proteins.

The Journal of biological chemistry·2001
Same author

SREBP cleavage-activating protein (SCAP) is required for increased lipid synthesis in liver induced by cholesterol deprivation and insulin elevation.

Genes & development·2001

Area of Science:

  • Pharmacology and Therapeutics
  • Cardiovascular Medicine
  • Hematology

Background:

  • Warfarin is a widely used oral anticoagulant for thromboembolic disorder management.
  • Achieving therapeutic anticoagulation while minimizing bleeding risk presents a significant clinical challenge due to warfarin's complex pharmacology.
  • Optimal warfarin dosing requires a deep understanding of its dose-response relationship and interaction profile.

Purpose of the Study:

  • To review current dosing recommendations for warfarin.
  • To provide practical guidelines for the safe and effective use of warfarin.
  • To highlight key considerations for warfarin therapy, including drug interactions and special populations.

Main Methods:

  • Review of existing literature and clinical guidelines on warfarin pharmacology and use.

Related Experiment Videos

  • Analysis of the dose-response relationship and International Normalized Ratio (INR) targets.
  • Consideration of concurrent heparin use and the role of loading doses.

    • Main Results:

    • Warfarin dosing is typically adjusted to maintain an INR of 2 to 3 for most indications.
    • Concurrent heparin administration for 4-5 days is necessary due to delayed suppression of clotting factors.
    • Loading doses of warfarin are not recommended and can increase bleeding risk.

    Conclusions:

    • Optimal warfarin therapy necessitates careful dose adjustment, consideration of drug interactions, and tailored management for specific patient groups, particularly the elderly.
    • Understanding the pharmacokinetics and pharmacodynamics of warfarin is crucial for preventing both thrombosis and hemorrhage.
    • Adherence to current dosing guidelines and practical management strategies ensures safer and more effective anticoagulation.